Jump to content

Vaccinia

From Wikipedia, the free encyclopedia
(Redirected from Orthopoxvirus vaccinia)
This article is about the virus related to smallpox vaccines. For the plant genus, see Vaccinium.
Not to be confused with vaccine.
Orthopoxvirus vaccinia
A TEM micrograp of "Vaccinia virus" virions
A TEM micrograph of Vaccinia virus virions
Virus classification Edit this classification
(unranked): Virus
Realm: Varidnaviria
Kingdom: Bamfordvirae
Phylum: Nucleocytoviricota
Class: Pokkesviricetes
Order: Chitovirales
Family: Poxviridae
Genus: Orthopoxvirus
Species:
Orthopoxvirus vaccinia
Member viruses[1]
Vaccinia
SpecialtyVirology
TypesProgressive vaccinia

The vaccinia virus (VACV or VV)[a] is a large, complex, enveloped virus belonging to the poxvirus family.[3] It has a linear, double-stranded DNA genome approximately 190 kbp in length, which encodes approximately 250 genes. The dimensions of the virion are roughly 360 × 270 × 250 nm, with a mass of approximately 5–10 fg.[4] The vaccinia virus is the source of the modern smallpox vaccine, which the World Health Organization (WHO) used to eradicate smallpox in a global vaccination campaign in 1958–1977. Although smallpox no longer exists in the wild, vaccinia virus is still studied widely by scientists as a tool for gene therapy and genetic engineering.

Smallpox had been an endemic human disease that had a 30% fatality rate. In 1796, the British doctor Edward Jenner proved that an infection with the relatively mild cowpox virus would also confer immunity to the deadly smallpox. Jenner referred to cowpox as variolae vaccinae (smallpox of the cow). However, the origins of the smallpox vaccine became murky over time,[5] especially after Louis Pasteur developed laboratory techniques for creating vaccines in the 19th century. Allan Watt Downie demonstrated in 1939 that the modern smallpox vaccine was serologically distinct from cowpox,[6] and vaccinia was subsequently recognized as a separate viral species. Whole-genome sequencing has revealed that vaccinia is most closely related to horsepox, and the cowpox strains found in Great Britain are the least closely related to vaccinia.[7]

Classification of vaccinia infections

[edit]

In addition to the morbidity of uncomplicated primary vaccination, transfer of infection to other sites by scratching, and post-vaccinial encephalitis, other complications of vaccinia infections may be divided into the following types:[8]: 391 

Origin

[edit]

Vaccinia virus is closely related to the virus that causes cowpox; historically the two were often considered to be one and the same.[9] The precise origin of vaccinia virus is unknown due to the lack of record-keeping, as the virus was repeatedly cultivated and passaged in research laboratories for many decades.[10] The most common notion is that vaccinia virus, cowpox virus, and variola virus (the causative agent of smallpox) were all derived from a common ancestral virus. There is also speculation that vaccinia virus was originally isolated from horses,[9] and analysis of DNA from an early (1902) sample of smallpox vaccine showed that it was 99.7% similar to horsepox virus.[11]

Virology

[edit]

Poxviruses are unique among DNA viruses because they replicate only in the cytoplasm of the host cell, outside of the nucleus.[12] Therefore, the large genome is required for encoding various enzymes and proteins involved in viral DNA replication and gene transcription. During its replication cycle, VV produces four infectious forms which differ in their outer membranes: intracellular mature virion (IMV), the intracellular enveloped virion (IEV), the cell-associated enveloped virion (CEV) and the extracellular enveloped virion (EEV).[13] Although the issue remains contentious, the prevailing view is that the IMV consists of a single lipoprotein membrane, while the CEV and EEV are both surrounded by two membrane layers and the IEV has three envelopes. The IMV is the most abundant infectious form and is thought to be responsible for spread between hosts. On the other hand, the CEV is believed to play a role in cell-to-cell spread and the EEV is thought to be important for long range dissemination within the host organism.[citation needed]

Multiplicity reactivation

[edit]

Vaccinia virus is able to undergo multiplicity reactivation (MR).[14] MR is the process by which two, or more, virus genomes containing otherwise lethal damage interact within an infected cell to form a viable virus genome. Abel[14] found that vaccinia viruses exposed to doses of UV light sufficient to prevent progeny formation when single virus particles infected host chick embryo cells, could still produce viable progeny viruses when host cells were infected by two or more of these inactivated viruses; that is, MR could occur. Kim and Sharp demonstrated MR of vaccinia virus after treatment with UV-light,[15] nitrogen mustard,[16] and X-rays or gamma rays.[17] Michod et al.[18] reviewed numerous examples of MR in different viruses, and suggested that MR is a common form of sexual interaction in viruses that provides the advantage of recombinational repair of genome damages.[additional citation(s) needed]

Host resistance

[edit]

Vaccinia contains within its genome genes for several proteins that give the virus resistance to interferons:

Use as a vaccine

[edit]
Site of a vaccinia injection, several days later.

Vaccinia virus infection is typically very mild and often does not cause symptoms in healthy individuals, although it may cause rash and fever. Immune responses generated from a vaccinia virus infection protects the person against a lethal smallpox infection. For this reason, vaccinia virus was, and still is, being used as a live-virus vaccine against smallpox. Unlike vaccines that use weakened forms of the virus being vaccinated against, the vaccinia virus vaccine cannot cause a smallpox infection because it does not contain the smallpox virus. However, certain complications and/or vaccine adverse effects occasionally arise. The chance of this happening is significantly increased in people who are immunocompromised. Approximately 1 to 2 people out of every 1 million people vaccinated could die as a result of life-threatening reactions to the vaccination.[21] The rate of myopericarditis with ACAM2000 is 5.7 per 1,000 of primary vaccinees.[22]

On September 1, 2007, the U.S. Food and Drug Administration (FDA) licensed a new vaccine ACAM2000 against smallpox which can be produced quickly upon need. Manufactured by Sanofi Pasteur, the U.S. Centers for Disease Control and Prevention stockpiled 192.5 million doses of the new vaccine (see list of common strains below).[23]

A smallpox vaccine, Imvanex, which is based on the Modified vaccinia Ankara strain, was approved by the European Medicines Agency (EMA) in 2013.[24] This strain has been used in vaccines during the 2022 monkeypox outbreak.[citation needed]

Vaccinia is also used in recombinant vaccines, as a vector for expression of foreign genes within a host, in order to generate an immune response. Other poxviruses are also used as live recombinant vaccines.[25]

History

[edit]

The original vaccine for smallpox, and the origin of the idea of vaccination, was Cowpox, described by Edward Jenner in 1798. The Latin term used for Cowpox was Variolae vaccinae, Jenner's own translation of "smallpox of the cow". That term lent its name to the whole idea of vaccination.[26] When it was realized that the virus used in smallpox vaccination was not, or was no longer, the same as cowpox virus, the name 'vaccinia' was used for the virus in smallpox vaccine. (See OED.) Vaccine potency and efficacy prior to the invention of refrigerated methods of transportation was unreliable. The vaccine would be rendered impotent by heat and sunlight, and the method of drying samples on quills and shipping them to countries in need often resulted in an inactive vaccine. Another method employed was the "arm to arm" method. This involved vaccinating an individual then transferring it to another as soon as the infectious pustule forms, then to another, etc. This method was used as a form of living transportation of the vaccine, and usually employed orphans as carriers. However, this method was problematic due to the possibility of spreading other blood diseases, such as hepatitis and syphilis, as was the case in 1861, when 41 Italian children contracted syphilis after being vaccinated by the "arm to arm" method.[27] Henry Austin Martin introduced a method for vaccine production from calves.[28]

In 1913, E. Steinhardt, C. Israeli, and R. A. Lambert grew vaccinia virus in fragments of pig corneal tissue culture.[29]

1950s US smallpox vaccine, produced by the National Drug Company in Philadelphia from vaccinia[30]

A paper published in 1915 by Fredrick W. Twort, a student of Willian Bulloch, is considered to be the beginning of modern phage research. He was attempting to grow vaccinia virus on agar media in the absence of living cells when he noted that many colonies of contaminating micrococci grew up and appeared mucoid, watery or glassy, and this transformation could be induced in other colonies by inoculation of the fresh colony with material from the watery colony. Using a microscope, he observed that bacteria had degenerated into small granules that stained red with Giemsa stain. He concluded that "...it [the agent of transformation] might almost be considered as an acute infectious disease of micrococci."[31]

In 1939 Allan Watt Downie showed that the smallpox vaccines being used in the 20th century and cowpox virus were not the same, but were immunologically related.[6][32]

2000–present

[edit]

In March 2007, a 2-year-old Indiana boy and his mother contracted a life-threatening vaccinia infection from the boy's father.[33] The boy developed the telltale rash over 80 percent of his body after coming into close contact with his father, who was vaccinated for smallpox before being deployed overseas by the United States Army. The United States military resumed smallpox vaccinations in 2002. The child acquired the infection due to eczema, which is a known risk factor for vaccinia infection. The boy was treated with intravenous immunoglobulin, cidofovir, and Tecovirimat (ST-246), a (then) experimental drug developed by SIGA Technologies.[34] On April 19, 2007, he was sent home with no after effects except for possible scarring of the skin.[33]

In 2010, the Centers for Disease Control and Prevention (CDC) reported that a woman in Washington had contracted vaccinia virus infection after digital vaginal contact with her boyfriend, a military member who had recently been vaccinated for smallpox. The woman had a history of childhood eczema, but she had not been symptomatic as an adult. The CDC indicated that it was aware of four similar cases in the preceding 12 months of vaccinia infection after sexual contact with a recent military vaccinee.[35] Further cases—also in patients with a history of eczema—occurred in 2012.[36]

Common strains

[edit]

This is a list of some of the well-characterized vaccinia strains used for research and vaccination.[citation needed]

  • Lister (also known as Elstree): the English vaccine strain used by Leslie Collier to develop heat stable vaccine in powdered form. Used as the basis for vaccine production during the World Health Organization Smallpox Eradication Campaign (SEC)
  • Dryvax (also known as "Wyeth"): the vaccine strain previously used in the United States, produced by Wyeth. Used in the SEC, it was replaced in 2008[37] by ACAM2000 (see below), produced by Acambis. It was produced as preparations of calf lymph which was freeze-dried and treated with antibiotics.
  • EM63: Russian strain used in the SEC
  • ACAM2000: The current strain in use in the US, produced by Acambis. ACAM2000 was derived from a clone of a Dryvax virus by plaque purification. It is produced in cultures of Vero cells.
  • Modified vaccinia Ankara (also known as MVA): a highly attenuated (not virulent) strain created by passaging vaccinia virus several hundred times in chicken embryo fibroblasts. Unlike some other vaccinia strains it does not make immunodeficient mice sick and therefore may be safer to use in humans who have weaker immune systems due to being very young, very old, having HIV/AIDS, etc.
  • LC16m8: an attenuated strain developed and currently used in Japan
  • CV-1: an attenuated strain developed in the United States and used there in the late 1960s- 1970s
  • Western Reserve
  • Copenhagen
  • Connaught Laboratories (Canada)

See also

[edit]

Notes

[edit]
  1. ^ Taxonomical species names were updated by the International Committee on Taxonomy of Viruses in June 2024, with Vaccinia virus being renamed Orthopoxvirus vaccinia.[2]

References

[edit]
  1. ^ "ICTV 9th Report (2011) Poxviridae". International Committee on Taxonomy of Viruses (ICTV). Archived from the original on 8 August 2022. Retrieved 17 December 2018.
  2. ^ "Taxon Details | ICTV". ictv.global. Retrieved 2024-08-30.
  3. ^ Ryan KJ, Ray CG, eds. (2004). Sherris Medical Microbiology (4th ed.). McGraw Hill. ISBN 978-0-8385-8529-0.
  4. ^ Johnson, L.; Gupta, A. K.; Ghafoor, A.; Akin, D.; Bashir, R. (2006). "Characterization of vaccinia virus particles using microscale silicon cantilever resonators and atomic force microscopy". Sensors and Actuators B Chemical. 115 (1): 189–197. doi:10.1016/j.snb.2005.08.047.
  5. ^ Baxby, Derrick (1981). Jenner's Smallpox Vaccine: The Riddle of Vaccinia Virus and Its Origin. Heinemann Educational Books. ISBN 978-0-435-54057-9.
  6. ^ a b Downie, AW (1939). "The Immunological Relationship of the Virus of Spontaneous Cowpox to Vaccinia Virus". British Journal of Experimental Pathology. 20 (2): 158–176. PMC 2065307.
  7. ^ Carroll, Darin S.; Emerson, Ginny L.; Li, Yu; Sammons, Scott; Olson, Victoria; Frace, Michael; Nakazawa, Yoshinori; Czerny, Claus Peter; Tryland, Morten; Kolodziejek, Jolanta; Nowotny, Norbert; Olsen-Rasmussen, Melissa; Khristova, Marina; Govil, Dhwani; Karem, Kevin; Damon, Inger K.; Meyer, Hermann (8 August 2011). "Chasing Jenner's Vaccine: Revisiting Cowpox Virus Classification". PLOS ONE. 6 (8): e23086. Bibcode:2011PLoSO...623086C. doi:10.1371/journal.pone.0023086. ISSN 1932-6203. PMC 3152555. PMID 21858000.
  8. ^ James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 978-0-7216-2921-6.
  9. ^ a b Huygelen C (1996). "Jenner's cowpox vaccine in light of current vaccinology". Verh. K. Acad. Geneeskd. Belg. (in Dutch). 58 (5): 479–536, discussion 537–538. PMID 9027132.
  10. ^ Henderson DA, Moss B (1999) [1988]. "Smallpox and Vaccinia". In Plotkin SA, Orenstein WA (eds.). Vaccines (3rd ed.). Philadelphia, Pennsylvania: WB Saunders. ISBN 978-0-7216-7443-8. Archived from the original on 2009-06-01. Retrieved 2017-09-17.
  11. ^ Schrick, Livia; Tausch, Simon H; Dabrowski, P. Wojciech; Damaso, Clarissa R; Esparza, José; Nitsche, Andreas (2017). "An Early American Smallpox Vaccine Based on Horsepox". New England Journal of Medicine. 377 (15): 1491–1492. doi:10.1056/NEJMc1707600. PMID 29020595.
  12. ^ Tolonen N, Doglio L, Schleich S, Krijnse Locker J (1 July 2001). "Vaccinia Virus DNA Replication Occurs in Endoplasmic Reticulum-enclosed Cytoplasmic Mini-Nuclei". Mol. Biol. Cell. 12 (7): 2031–46. doi:10.1091/mbc.12.7.2031. PMC 55651. PMID 11452001.
  13. ^ Smith GL, Vanderplasschen A, Law M (1 December 2002). "The formation and function of extracellular enveloped Vaccinia virus". J. Gen. Virol. 83 (Pt 12): 2915–31. doi:10.1099/0022-1317-83-12-2915. PMID 12466468.
  14. ^ a b ABEL P (August 1962). "Multiplicity reactivation and marker rescue with vaccinia virus". Virology. 17 (4): 511–9. doi:10.1016/0042-6822(62)90150-2. PMID 13858909.
  15. ^ Sharp DG, Kim KS (July 1966). "Multiplicity reactivation and radiation survival of aggregated vaccinia virus. Calculation of plaque titer based on MR and particle aggregation seen in the electron microscope". Virology. 29 (3): 359–66. doi:10.1016/0042-6822(66)90211-X. PMID 5922451.
  16. ^ Kim KS, Sharp DG (February 1967). "Multiplicity reactivation of vaccinia virus particles treated with nitrogen mustard". J. Virol. 1 (1): 45–9. doi:10.1128/JVI.1.1.45-49.1967. PMC 375503. PMID 5623957.
  17. ^ Kim KS, Sharp DG (January 1968). "Multiplicity reactivation of gamma- and x-irradiated Vaccinia virus in L cells". Radiat. Res. 33 (1): 30–6. Bibcode:1968RadR...33...30K. doi:10.2307/3572239. JSTOR 3572239. PMID 5634978.
  18. ^ Michod RE, Bernstein H, Nedelcu AM (2008). "Adaptive value of sex in microbial pathogens". Infect Genet Evol. 8 (3): 267–285. doi:10.1016/j.meegid.2008.01.002. PMID 18295550.
  19. ^ a b Davies MV, Chang HW, Jacobs BL, Kaufman RJ (1 March 1993). "The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms". J. Virol. 67 (3): 1688–1692. doi:10.1128/JVI.67.3.1688-1692.1993. PMC 237544. PMID 8094759.
  20. ^ Warren, Luigi; Manos, Philip D.; Ahfeldt, Tim; Loh, Yuin-Han; Li, Hu; Lau, Frank; Ebina, Wataru; Mandal, Pankaj K.; Smith, Zachary D.; Meissner, Alexander; Daley, George Q.; Brack, Andrew S.; Collins, James J.; Cowan, Chad; Schlaeger, Thorsten M.; Rossi, Derrick J. (2010). "Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNA". Cell Stem Cell. 7 (5): 618–630. doi:10.1016/j.stem.2010.08.012. PMC 3656821. PMID 20888316.
  21. ^ "Side Effects of Smallpox Vaccination | Smallpox | CDC". 2017-07-12. Archived from the original on 2022-05-26. Retrieved 2022-05-25.
  22. ^ Rao, Agam K.; Petersen, B. W.; Whitehill, F.; Razeq, J. H.; Isaacs, S. N.; Merchlinsky, M. J.; Campos-Outcalt, D.; Morgan, R. L.; Damon, I.; Sánchez, P. J.; Bell, B. P. (2022-06-03). "Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination | Smallpox | CDC". MMWR. Morbidity and Mortality Weekly Report. 71 (22): 734–742. doi:10.15585/mmwr.mm7122e1. PMC 9169520. PMID 35653347. Archived from the original on 2022-08-08. Retrieved 2022-08-08.
  23. ^ Heilprin, John (1 September 2007). "FDA approves new smallpox vaccine". Houston Chronicle. AP. Archived from the original on 26 May 2018. Retrieved 25 May 2018.
  24. ^ "European public assessment report summary: Imvanex". 2018-09-17. Archived from the original on 2018-06-20. Retrieved 2014-05-19.
  25. ^ Vanderplasschen, A.; Pastoret, P.-P. (December 2003). "The Uses of Poxviruses as Vectors". Current Gene Therapy. 3 (6): 583–595. doi:10.2174/1566523034578168. PMID 14683453.
  26. ^ Baxby, D (1999). "Edward Jenner's Inquiry; a bicentenary analysis". Vaccine. 17 (4): 301–307. doi:10.1016/S0264-410X(98)00207-2. PMID 9987167.
  27. ^ Tucker, Jonathan B. (2001). Scourge: The Once and Future Threat of Smallpox. New York: Grove/Atlantic Inc.
  28. ^ Esparza, José; Lederman, Seth; Nitsche, Andreas; Damaso, Clarissa R. (2020-06-19). "Early smallpox vaccine manufacturing in the United States: Introduction of the "animal vaccine" in 1870, establishment of "vaccine farms", and the beginnings of the vaccine industry". Vaccine. 38 (30): 4773–4779. doi:10.1016/j.vaccine.2020.05.037. ISSN 0264-410X. PMC 7294234. PMID 32473878.
  29. ^ Steinhardt E, Israeli C, Lambert RA (September 1913). "Studies on the cultivation of the virus of vaccinia". J Inf Dis. 13 (2): 294–300. doi:10.1093/infdis/13.2.294. JSTOR 30073371. Archived from the original on 2022-03-31. Retrieved 2019-09-11.
  30. ^ "Tube for smallpox vaccine with two sealed needles". Thackray Museum of Medicine Collections Online. 474.058. Archived from the original on 2024-05-29. Retrieved 2024-05-29.
  31. ^ Waldor, Matthew K.; Friedman, David I.; Adhya, Sankar Lal, eds. (2005). Phages : their role in bacterial pathogenesis and biotechnology. Washington, D.C.: ASM Press. ISBN 1-55581-307-0. OCLC 57557385.
  32. ^ Tyrrell, D. A. J.; McCarthy, K. (1990). "Allan Watt Downie. September 1901 – 26 January 1988". Biographical Memoirs of Fellows of the Royal Society. 35: 98–112. doi:10.1098/rsbm.1990.0004. PMID 11622284.
  33. ^ a b Centers for Disease Control and Prevention (CDC) (2007). "Household transmission of vaccinia virus from contact with a military smallpox vaccinee—Illinois and Indiana, 2007". Morbidity and Mortality Weekly Report. 56 (19): 478–81. PMID 17510612. Archived from the original on 2021-03-10. Retrieved 2017-09-17.
  34. ^ "SIGA's Smallpox Drug Candidate Administered to Critically Ill Human Patient" (Press release). SIGA Technologies. 2007-03-17. Archived from the original on 2018-07-20. Retrieved 2018-07-20.
  35. ^ Centers for Disease Control and Prevention (CDC) (2010). "Vaccinia Virus Infection After Sexual Contact with a Military Smallpox Vaccinee—Washington, 2010". Morbidity and Mortality Weekly Report. 59 (25): 773–75. PMID 20592687. Archived from the original on 2021-04-23. Retrieved 2017-09-17.
  36. ^ Centers for Disease Control and Prevention (CDC) (March 2013). "Secondary and tertiary transmission of vaccinia virus after sexual contact with a smallpox vaccinee—San Diego, California, 2012". Morbidity and Mortality Weekly Report. 62 (8): 145–7. PMC 4604863. PMID 23446513. Archived from the original on 2021-03-09. Retrieved 2017-09-17.
  37. ^ "Notice to Readers: Newly Licensed Smallpox Vaccine to Replace Old Smallpox Vaccine". MMWR Morb. Mortal. Wkly. Rep. 57 (8): 207–8. February 29, 2008. Archived from the original on May 20, 2022. Retrieved September 17, 2017.

Further reading

[edit]
[edit]
Retrieved from "http://en.wiki.x.io/w/index.php?title=Vaccinia&oldid=1243956985"